Drug interactions
Eslicarbazepine + Ponatinib
Severity: Major
Eslicarbazepine and Ponatinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Eslicarbazepine may decrease ponatinib exposure via CYP3A4 induction. Reduced exposure may impair efficacy in leukemia.
What this interaction means in plain words
Eslicarbazepine and Ponatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Eslicarbazepine belongs to Central Nervous System; Ponatinib belongs to Oncology.
Why it happens
CYP3A4 induction increases ponatinib clearance.
What to do
Avoid unless benefit outweighs risk; monitor hematologic and molecular response.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Eslicarbazepine and Ponatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Eslicarbazepine
- Eslicarbazepine + Mavacamten Contraindicated
- Eslicarbazepine + Rilpivirine Contraindicated
- Artemether / lumefantrine + Eslicarbazepine Major
- Avapritinib + Eslicarbazepine Major
- Bedaquiline + Eslicarbazepine Major
- Benzhydrocodone / acetaminophen + Eslicarbazepine Major
Other interactions of Ponatinib
Frequently asked questions
Can I take Eslicarbazepine with Ponatinib?
MediHelp rates the interaction as major. Eslicarbazepine and Ponatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Eslicarbazepine may decrease ponatinib exposure via CYP3A4 induction. Reduced exposure may impair efficacy in leukemia.
How serious is the interaction between Eslicarbazepine and Ponatinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid unless benefit outweighs risk; monitor hematologic and molecular response.
What other medicines interact with Eslicarbazepine?
MediHelp also lists interactions of Eslicarbazepine with, for example, Mavacamten, Rilpivirine, Artemether / lumefantrine. The full list is on the Eslicarbazepine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
